Chemoimmunotherapy followed by lenalidomide consolidation is tolerated and extends PFS and OS in CLL patients.
Chronic Lymphocytic Leukemia
In analyzing over 8,300 mosaic chromosomal alterations in UK Biobank participants, Harvard researchers uncovered specific alterations that may predict for CLL.
Most CLL patients treated with FCR will experience long-term remissions, but patients who relapse within 24 months have a dismal prognosis.
Findings from the MCC-Spain study suggest that in some cases, CLL could be prevented by modifying dietary habits.
Overall response was strong even in high-risk patients (over age 65, with 17p deletion, with prior ibrutinib therapy, and mutations of BTK and PLCγ2).
FDA warns, however, about the possibility of TLS due to rapid tumor cell destruction.
Elimination of chemotherapy from our combination regimens should be a shared goal among researchers that will move us a step closer to more patient-friendly and scientifically driven therapies for CLL.
Until the superiority of novel agents is proven for all prognostically relevant subgroups of patients with CLL, we believe chemoimmunotherapy continues to have a role.
In CAPTIVATE, first-line ibrutinib plus venetoclax yielded a high rate of undetectable residual disease, without new safety signals, in chronic lymphocytic leukemia.
Achieving undetectable MRD after chemoimmunotherapy predicted longer progression-free and overall survival in CLL patients.